Fierce Pharma’s Fierce Madness tournament has been narrowed down to a field of eight. The remaining ‘teams’ are Ocrevus, Phexxi, Johnson & Johnson, Adakveo, Bayer, Pfizer-BioNTech, Nurtec, and Dovato. This year’s event is focusing on each company’s DTC ad campaign.

Just weeks after the FDA approved Breyanzi, Bristol Myers Squibb’s therapy to treat CAR-T lymphoma, the company has announced plans to expand its Devens, MA location with a new 244,000 square foot cell therapy site.

Fierce Pharma, in conjunction with Evaluate consensus sales estimates, has put together a list of what expects to be the most anticipated new drug launches in 2021.

TG Therapeutics has announced that it has received an accelerated FDA approval for Ukoniq (umbralisib) used to treat for two types of blood cancer.

Meitheal Pharmaceuticals, a generic drug maker, has recalled one lot of cisatracurium besylate, a muscle relaxant. The lot was distributed between August 19, 2020 and January 4, 2021.

With COVID-19 vaccinations stalling, a new antibody combination treatment by Eli Lilly has shown positive Phase III data of more than 1,000 high-risk patients with COVID.

2020 had its ups and downs but in the world of biopharma there were some big M&A deals that took place. Click here to read about the top 10 M&A of 2020.

In an effort to market direct-to-consumer, Jazz has launched a new marketing campaign and ramped up its salesforce for Sunosi with 50 new employees.